This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 1998;280:7-8.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE WORLD'S first wide-scale efficacy testing of a vaccine to prevent AIDS received the go-ahead from the Food and Drug Administration last month, although some scientists remain skeptical about its prospects for success.

The approval allows VaxGen, Inc, a South San Francisco, Calif, biotechnology company that developed the experimental vaccine, called AIDSVAX, to go forward with a 3-year, placebo-controlled phase 3 efficacy trial involving 5000 volunteers at high risk for HIV infection in as many as 40 clinics in the United States and Canada. Once the necessary approvals are secured from Thai health officials, the company expects to begin enrolling 2500 volunteers in 16 clinics in Thailand later this year in a similar trial involving a slightly different vaccine formulation.

VaxGen planned to begin recruiting US volunteers this month in Chicago, Ill, Denver, Colo, Los Angeles, Calif, Philadelphia, Pa, and St Louis, Mo, extending efforts to other . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?